国泰海通证券股份有限公司 关于上海南方模式生物科技股份有限公司 实际控制人解除一致行动关系的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通证券"、"保荐机构"）作 为上海南方模式生物科技股份有限公司（以下简称"南模生物"、"公司"）首次 公开发行股票并在科创板上市的持续督导保荐机构，根据《证券发行上市保荐业 务管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司 自律监管指引第11号——持续督导》《上海证券交易所科创板上市公司自律监管 指引第1号——规范运作》等有关规定，对实际控制人解除一致行动关系的事项 进行了核查，具体情况如下： 一、《一致行动协议》签署及履行情况 截至本核查意见签署日，上海砥石企业管理咨询有限公司（以下简称"砥石 咨询"）持有公司27,771,000股股份，持股比例为35.62%，系公司控股股东。公司 实际控制人、董事长、核心技术人员费俭先生未直接持有公司股份，通过砥石咨 询和上海璞钰企业管理咨询合伙企业（有限合伙）（以下简称"璞钰咨询"）间接 持有公司841.34万股，占比10.79%；公司实际控制人、董事、总经理王明俊先生 未直接持有公司股份，通过砥石咨询和 ...

上海南方模式生物科技股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 您可使用手机"扫一扫"或进入"注册会计师行业统一监管理台（h acc.mof.gov.cn 报告编码:浙25BFYHBK72 www.zhcpa.cn 内部控制审计报告 中汇会审[2025]6299号 上海南方模式生物科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了上海南方模式生物科技股份有限公司(以下简称南模生物公司)2024年12 月31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》《企业内部控制 评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是南模生物 公司董事会的责任。 二、注册会计 ...

上海南方模式生物科技股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 录 II 本鉴证报告仅供南模生物公司年度报告披露时使用,不得用作任何其他目的。 我们同意将本鉴证报告作为南模生物公司年度报告的必备文件,随同其他文件一起 报送并对外披露。 二、管理层的责任 | | 页 次 | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 | 1-2 | | 二、上海南方模式生物科技股份有限公司关于 2024年度募集资金 | | | 存放与使用情况的专项报告 | 3-11 | 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times ...

上海南方模式生物科技股份有限公司 2024 年度审计报告 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhepa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 E明该审计报告是否由具有执业许可的会计师事 师行业绩一监管平台(http://acc.mof.gov.cn) 您可使用手机"扫一扫"或进入"注册会计师行业线 报告编码:浙25H4 审计报告 中汇会审[2025]6295号 上海南方模式生物科技股份有限公司全体股东: 一、审计意见 我们审计了上海南方模式生物科技股份有限公司(以下简称南模生物公司)财 务报表,包括2024年12月31日的合并及母公司资产负债表,2024年度的合并及母 公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及财 务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制, 公允反映了 ...

Financial Performance - The company plans not to distribute profits for the fiscal year 2024, with no cash dividends or stock bonuses, and will roll over the undistributed profits to the next fiscal year[7]. - The company has not achieved profitability since its listing, indicating ongoing financial challenges[5]. - The company reported a significant increase in revenue, achieving a total of $150 million for the fiscal year, representing a 25% year-over-year growth[17]. - The company's operating revenue for 2024 reached ¥381,239,513.99, representing a 4.01% increase compared to ¥366,548,781.43 in 2023[24]. - The net profit attributable to shareholders was ¥6,495,504.05, a significant turnaround from a loss of ¥20,582,607.05 in the previous year[24]. - The net cash flow from operating activities increased by 256.35% to ¥71,564,019.48, up from ¥20,082,247.66 in 2023[24]. - The basic earnings per share improved to ¥0.08 from a loss of ¥0.26 in 2023[25]. - The company achieved a revenue of 381.24 million yuan, representing a year-on-year growth of 4.01%[35]. - The net profit attributable to the parent company was approximately 6.50 million yuan, marking a turnaround from loss to profit[35]. - The company reported a decrease in financial expenses, mainly due to increased exchange gains and reduced interest expenses[134]. Risk Management - The company has detailed potential risks in its operations, which are outlined in the report[5]. - The company has a comprehensive risk awareness regarding future plans and development strategies[8]. - The company is at risk of significant profit fluctuations due to potential industry slowdowns and reduced order volumes, which could impact its profitability[113]. - The company faces risks related to the potential obsolescence of its core gene editing technologies if new, more efficient methods emerge and it fails to adapt[114]. - The company is exposed to risks from potential changes in tax incentives and government subsidies, which could affect profitability[123]. - The company faces risks related to market competition, particularly from domestic and international peers in the gene-modified animal model sector[117]. Research and Development - The company is investing $10 million in R&D for new technologies aimed at improving drug development processes[17]. - Research and development expenses accounted for 19.67% of operating revenue, a decrease of 2.22 percentage points from 21.89% in 2023[25]. - The total R&D investment for the year was ¥74,981,116.58, a decrease of 6.55% compared to the previous year[99]. - The company has developed over 21,000 models, including more than 13,000 standardized models and over 8,200 customized models[36]. - The company has developed a series of humanized animal models, including drug target humanized models and rare disease models, to meet the growing demand for precision medicine[171]. - The company is focusing on expanding its research and development capabilities, particularly in molecular biology and biochemistry, to drive innovation[199]. Market Expansion - The company is expanding its market presence in Europe, targeting a 15% market share by the end of the next fiscal year[17]. - The company is actively expanding its overseas market presence, contributing to faster growth in international business revenue[26]. - The company is exploring new strategies to optimize its supply chain and reduce operational costs[198]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 200 million allocated for potential deals[197]. - The company is focused on expanding its market presence and enhancing its product offerings through new technology development[198]. - The company is committed to enhancing its core competencies by fostering a multidisciplinary team capable of driving advanced research initiatives[104]. Corporate Governance - A standard unqualified audit report was issued by Zhonghui Certified Public Accountants for the company[6]. - The board of directors and management have confirmed the accuracy and completeness of the annual report, assuming legal responsibility for any misstatements[5]. - The company has not disclosed any special arrangements in corporate governance[10]. - The company has established a stock incentive plan for 2025, with a total of 1.3 million restricted shares, of which 1.04 million shares will be granted initially to 84 individuals[51]. - The company appointed Wang Mingjun as the acting CFO following the resignation of the previous CFO Zhou Rongxin due to personal reasons[200]. Product Development - New product launches included a cutting-edge gene editing tool, expected to enhance research capabilities and drive future sales[17]. - The company has developed various gene-modified mouse models for specific applications, including humanized models for drug testing and disease research[95]. - The company is developing a humanized antibody screening platform to support personalized medicine and drug development[172]. - The company has established a comprehensive "mouse hospital" platform to support various research needs in genetic function studies and pharmacological efficacy[100]. Customer Engagement - User data showed a 40% increase in active users, reaching 1.2 million by the end of the fiscal year[17]. - User data indicates a steady increase in customer engagement and retention rates, reflecting positive market reception[198]. - The company has a strong customer base, providing services to over 950 research clients and more than 720 industrial clients, including renowned universities and pharmaceutical companies[111]. Financial Strategy - The company is focusing on cost control by implementing comprehensive budget management and optimizing procurement processes[50]. - The company aims to broaden its financing channels and improve the efficiency of fundraising to support sustainable and high-quality development[178]. - The company is committed to establishing a comprehensive service system that aligns with the demands of precision medicine, focusing on high-growth potential clients and partners[187].

上海南方模式生物科技股份有限公司 董 事 会 2025 年 4 月 29 日 上海南方模式生物科技股份有限公司董事会 根据中国证券监督管理委员会《上市公司独立董事管理办法》《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交易所科创 板上市规则》等法律、行政法规及规范性文件的有关要求，上海南方模式生物科 技股份有限公司（以下简称"公司"）董事会就公司在任独立董事任海峙、单飞跃、 邵正中的独立性情况进行评估，并出具如下专项意见： 经核查公司在任独立董事任海峙、单飞跃、邵正中的任职经历，上述人员未 在公司担任除独立董事及董事会专门委员或主任委员以外的任何职务，也未在公 司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系、重大 业务往来或其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立 性的情况。因此，董事会认为公司独立董事符合《上市公司独立董事管理办法》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》中对独立 董事独立性的相关要求。 关于独立董事独立性情况评估的专项意见 ...

2024 年度独立董事述职报告 上海南方模式生物科技股份有限公司 2024 年度独立董事述职报告（任海峙） 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 任海峙，硕士研究生学历。1992 年 8 月至今历任上海立信会计金融学院教 师、副教授；现任上海观安信息技术股份有限公司独立董事，格力博（江苏）股 份有限公司独立董事，2022 年 8 月至 2025 年 2 月任江苏常荣电器股份有限公司 独立董事；2025 年 4 月至今任张家港中环海陆高端装备股份有限公司独立董事； 2020 年 4 月至今任南模生物独立董事。 报告期内，本人作为上海南方模式生物科技股份有限公司（以下简称"公司" 或"南模生物"）的独立董事，严格按照《公司法》《证券法》《上市公司独立 董事管理办法》《上市公司治理准则》《上海证券交易所科创板股票上市规则》 等法律法规、规范性文件及《公司章程》《独立董事工作制度》等规定，忠实、 勤勉、独立地履行独立董事的职责,积极出席公司股东大会、董事会及各专门委 员会会议，对公司董事会审议的相关事项发表公正、客观的审核意见，依法维护 公司及全体股东利益，尤其是中小股东的合法权益。现将本人 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥88,396,140.55, representing a 6.59% increase compared to ¥82,932,302.56 in the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥966,819.05, significantly improved from a loss of ¥12,897,060.70 in the previous year, marking a 92.50% reduction in losses[4][8]. - The basic and diluted earnings per share were both -¥0.01, an improvement from -¥0.17 in the same period last year[4]. - Operating profit improved to a loss of CNY 2,239,745.43 from a loss of CNY 12,998,602.81 year-over-year[18]. - Other comprehensive income after tax showed a loss of CNY 43,265.75, improving from a loss of CNY 91,122.93 in the previous year[19]. Cash Flow - The net cash flow from operating activities was a negative ¥26,746,493.35, slightly improved from a negative ¥28,394,359.82 in the same period last year[4]. - Cash inflow from operating activities totaled $68,065,103.00, slightly up from $67,757,018.71 in the previous period[22]. - Total cash outflow from operating activities was $94,811,596.35, compared to $96,151,378.53 in the prior period, showing a decrease in cash outflows[22]. - The net increase in cash and cash equivalents was -$119,506,029.02, compared to a positive increase of $10,740,267.10 in the prior period, indicating a cash depletion[23]. - The ending balance of cash and cash equivalents was $76,708,816.58, down from $108,343,188.50 at the end of the previous period[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,911,115,609.92, a decrease of 0.95% from ¥1,929,356,534.07 at the end of the previous year[5]. - Total liabilities decreased to CNY 227,976,260.32 from CNY 246,356,013.57, a reduction of 7.4%[14]. - Total current assets slightly decreased to ¥1,145,527,515.74 from ¥1,148,284,749.04, a reduction of about 0.2%[12]. - Total non-current assets decreased to ¥765,588,094.18 from ¥781,071,785.03, a reduction of approximately 1.98%[13]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 6,252[10]. - The largest shareholder, Shanghai Dish Consulting Co., Ltd., holds 27,771,000 shares, accounting for 35.62% of total shares[10]. Research and Development - Research and development expenses totaled ¥19,755,542.27, accounting for 22.35% of operating revenue, a decrease of 0.96 percentage points from 23.31% in the previous year[5]. - The company reported a decrease in research and development expenses to CNY 19,755,542.27 from CNY 19,334,427.95, indicating a focus on cost management[18]. - The company has no significant new product or technology developments reported in the conference call[12]. Investment Activities - Total cash inflow from investment activities was $691,876,563.18, significantly higher than $296,496,310.15 in the prior period[22]. - The net cash flow from investment activities was -$88,994,587.15, contrasting with a positive $60,121,373.98 in the previous period, reflecting increased investment outflows[22]. - The company made significant investments totaling $777,000,000.00, compared to $230,000,000.00 in the previous period, indicating aggressive expansion strategies[22]. Cost Management - The company plans to continue enhancing cost control through measures such as optimizing production processes and improving delivery timeliness[8]. - Total operating costs decreased to CNY 94,524,575.57 from CNY 99,746,760.11, representing a reduction of 5.4%[18].

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0800 | -0.2600 | 130.77 | -0.0700 | | 每股净资产（元） | 21.59 | 22.28 | -3.1 | 22.65 | | 每股公积金(元) | 20.08 | 20.11 | -0.15 | 20.04 | | 每股未分配利润(元) | 1.04 | 1.12 | -7.14 | 1.40 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 3.81 | 3.67 | 3.81 | 3.03 | | 净利润(亿元) | 0.06 | -0.21 | 128.57 | -0.05 | | 净资产收益率(%) | 0.38 | -1.17 | 132.48 | -0.31 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 3031.11万股，累计占流通股比 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 4 月 30 日（星期三）下午 13:00-14:00 会议召开地点：上海证券交易所上证路演中心（网址 ： https://roadshow.sseinfo.com/） 证券代码：688265 证券简称：南模生物 公告编号：2025-022 上海南方模式生物科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会 的公告 董事长：费俭先生 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 4 月 23 日（星期三）至 4 月 29 日（星期二）16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过上海南方模式生物科技股 份有限公司（以下简称"公司"）邮箱 ir@modelorg.com 进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 公司将于 2025 年 4 月 29 日发布公司《2024 年年度报告》《2025 年第一季度 报告》，为便于广大投资者更全面深入地了解公司 ...